4086555 — Vedolizumab Powder-inj
Cite this view
HANK Price Transparency. (n.d.). Vedolizumab Powder-inj (CDM 4086555) negotiated rates. PPMan price-transparency data, derived from CMS-required hospital MRFs. Retrieved , from http://ppman.hank.ai/transparency/code/4086555?code_type=CDM
“Vedolizumab Powder-inj (CDM 4086555) negotiated rates.” HANK Price Transparency, http://ppman.hank.ai/transparency/code/4086555?code_type=CDM. Accessed .
“Vedolizumab Powder-inj (CDM 4086555) negotiated rates,” HANK Price Transparency, accessed , http://ppman.hank.ai/transparency/code/4086555?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital machine-readable files (45 CFR 180). See methodology.
Usually $23,438–$27,962 (25th–75th percentile) across 1 hospital · 3 payers.
“Negotiated” is the hospital’s negotiated facility rate for this CDM 4086555 — the consumer-grade median across the country. It covers the facility charge only; the surgeon’s and anesthesiologist’s fees are billed separately.
Per-month price trends are temporarily unavailable while we rebuild them on quality-filtered rates. The medians, percentiles, and per-hospital rates on this page are the quality-filtered figures.
Hospital rates (per row)
Showing consumer-grade rates only. Flagged / outlier filings (excluded from the medians above) are hidden — tick “Show flagged / outlier rates” to include them.
| Hospital | Payer | Plan | Negotiated rate | Gross | Cash | Observed | Source |
|---|---|---|---|---|---|---|---|
| PRESENTATION MEDICAL CENTER Both | NextBlue | Medicare Advantage | $18,914.00 | $29,434.00 | $26,491.00 | 2026-05-27 | MRF ↗ |
| PRESENTATION MEDICAL CENTER Both | Sanford Health Plan | Commercial | $27,962.00 | $29,434.00 | $26,491.00 | 2026-05-27 | MRF ↗ |
| PRESENTATION MEDICAL CENTER Both | HealthPartners | Commercial | $27,962.00 | $29,434.00 | $26,491.00 | 2026-05-27 | MRF ↗ |